Time has flown since our 19th Biennial Symposium in Fort Collins this Spring. It seems like yesterday we were gathered together, connecting with colleagues and learning about the latest research. But time waits for nobody, and since then our organization has been actively representing the veterinary pharmacology community in several ways.

At the biennial we held a special session on Compounding, at which we began our in-depth discussions of this enduring issue. As a scientific organization representing veterinary pharmacologists in wide range of sectors, our interest in Compounding covers the gamut of considerations, including the clinical use of compounded drugs, the study of benefits and risks of using compounded drugs, the regulation of compounded drugs, and the potential for inappropriate compounding to copy approved animal drugs. Based on these discussions, we were well-prepared to construct a meaningful comment on the FDA-CVM’s Draft Guidance for Industry on Compounding Animal Drugs from Bulk Drug Substances. A huge thank-you goes to committed members of our organization, including Chantal Lainesse, Virginia Fajt, Jane Owens and Gigi Davidson for finalizing these comments. For those who would like to review our comments, or refer to them in the future, they are available on our website.

As a follow up to the Compounding issue, the FDA has also asked for input to Docket No. FDA-105-N-1196 – List of bulk drug substances that can be used by an outsourcing facility to compound drugs for using in animals. Their request is for nomination for Appendix A of this document. The AAVPT is contributing to this process through our representation on the AVMA Council of Biologics and Therapeutic Agents. Members who would like more information on the nominated drugs can contact Jane Owens (jane.owens@elanco.com).

In October we were notified of another call for comments from the FDA, this time about the international rescheduling of ketamine. The proposed rescheduling would severely limit the availability of ketamine as an anesthetic drug to veterinarians in the US. The turnaround time for these comments was very short, but the AAVPT put together a meaningful response, which is also available on our website. As members of a global community that is committed to animal and human health under the umbrella of One Health, it was important for us to contribute to this debate.

We look forward to working with you all in the New Year, so please take a minute to update your profile on our website to ensure that we can contact you and keep you up to date. Also, we will soon start planning our 20th biennial to be held Washington DC in 2017. If any members would like to be involved, or have programming ideas they would like the committee to consider, please contact Dr Virginia Fajt at vfajt@tamu.edu.

Wishing you all a happy and peaceful Holiday Season!

Ronette Gehring
AAVPT President 2015-2017